Quince Therapeutics, Inc.

Quince Therapeutics, Inc. announced the implementation of a 1-for-20 reverse stock split, previously approved by stockholders. The Certificate of Amendment was filed on June 26, 2026, becoming effective at 11:59 pm ET on June 29, 2026. The company's common stock will commence trading on a split-adjusted basis on the Nasdaq Global Select Market at market open on June 30, 2026, under a new CUSIP number while retaining the QNCX ticker symbol. The split will reduce the number of outstanding shares from approximately 19.56 million to 0.98 million, with fractional shares being paid in cash.

Quince Therapeutics, Inc. announced that it has regained compliance with Nasdaq's continued listing requirements. The company had previously received a notice on March 17, 2026, for failing to maintain a minimum market value of listed securities of $50,000,000. On May 20, 2026, Nasdaq confirmed that Quince Therapeutics now complies with the stockholders' equity rule, based on its reported $15,672,000 in stockholders' equity for the quarter ended March 31, 2026, thereby closing the matter.

Quince Therapeutics announced positive Phase 2a data for LAM-001, an inhaled rapamycin, in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study demonstrated clinically meaningful improvements across functional, hemodynamic, and biomarker measures, including a 67.4-meter improvement in 6MWD and a 33.9% reduction in PVR in PH-ILD patients. Based on these encouraging results, the company plans to initiate a Phase 2b trial in PH-ILD in mid-2026, with data expected in the first quarter of 2028, and also has ongoing and planned studies for other indications.

Quince Therapeutics acquired Orphai Therapeutics, a clinical-stage biotechnology company, bringing the lead program LAM-001 into its pipeline. Concurrent with the acquisition, Quince secured up to $187 million in private placement financing, including $115 million upfront, to advance LAM-001. The financing, combined with existing cash, is expected to fund operations through the end of 2028 and support multiple clinical milestones, including Phase 2b PH-ILD data in Q1 2028 and Phase 2 BOS data in Q1 2027. Promising Phase 2a data for LAM-001 in PH-ILD were also announced, showing clinically meaningful improvements.

Quince Therapeutics announced the cessation of clinical development for its lead asset, eDSP, following the failure of its Phase 3 NEAT clinical trial to meet its primary endpoint. This significant setback led management to issue a going concern warning, citing insufficient cash to fund operations for the next twelve months and the need to evaluate strategic alternatives. Despite reporting a net income of $35.9 million for Q1 2026, driven by non-operating fair value adjustments and an intangible asset impairment charge, the company faces substantial operational challenges.

Quince Therapeutics, Inc. announced it has regained compliance with the Nasdaq minimum bid price requirement, with its common stock closing at or above $1.00 for 10 consecutive business days. However, the company has not yet regained compliance with Nasdaq's $50,000,000 market value of listed securities (MVLS) requirement. Quince Therapeutics has until September 14, 2026, to regain MVLS compliance, with no assurance of success.

Quince Therapeutics, Inc. (QNCX) announced its 2026 Annual Meeting of Stockholders will be held virtually on Thursday, June 11, 2026. Key proposals include the election of a Class I director, approval of an amendment to effect a reverse stock split ranging from 1-for-10 to 1-for-100, ratification of BDO USA, P.C. as the independent auditor, and an advisory vote on executive compensation. Stockholders of record as of April 23, 2026, are eligible to vote.

Quince Therapeutics, Inc. announced the appointment of June Bray as a Class I independent director, effective April 22, 2026. This appointment increases the company's Board of Directors to four members. Ms. Bray will also serve on the Nominating & Governance, Audit, and Compensation Committees, receiving standard non-employee director compensation, including an annual retainer of $38,000 for board service and additional retainers for committee roles.

Quince Therapeutics, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2025. The company reported an aggregate market value of approximately $64.0 million for common stock held by non-affiliates as of June 30, 2025. The filing indicates the company is a non-accelerated filer and a smaller reporting company.

Quince Therapeutics, Inc. (QNCX) announced the implementation of a 1-for-10 reverse stock split, following stockholder approval on June 4, 2025. The company's board of directors approved the action, and the Certificate of Amendment was filed on April 9, 2026, becoming effective at 11:59 pm Eastern Time on April 10, 2026. This move is typically undertaken to increase the per-share trading price, often to meet minimum bid price requirements for continued listing on exchanges like the Nasdaq Global Select Market. The reverse stock split will uniformly affect all stockholders, converting every ten existing shares into one new share, with cash paid in lieu of fractional shares.